Twist Bioscience (NASDAQ:TWST) Price Target Raised to $115.00

Twist Bioscience (NASDAQ:TWST) had its target price upped by Robert W. Baird from $113.00 to $115.00 in a research report released on Tuesday morning, MarketBeat Ratings reports. Robert W. Baird currently has an outperform rating on the stock.

Several other brokerages also recently commented on TWST. Barclays increased their price objective on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Piper Sandler initiated coverage on Twist Bioscience in a report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Canaccord Genuity Group lifted their target price on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a report on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus target price of $98.30.

Twist Bioscience Trading Down 5.2%

NASDAQ:TWST opened at $108.99 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.42. The firm has a 50-day moving average of $88.31 and a 200-day moving average of $63.98. The company has a market cap of $6.83 billion, a PE ratio of -49.09 and a beta of 2.14. Twist Bioscience has a one year low of $23.30 and a one year high of $115.56.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 EPS. As a group, equities research analysts expect that Twist Bioscience will post -2.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the sale, the insider directly owned 105,141 shares in the company, valued at $9,436,404.75. This represents a 11.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total transaction of $673,440.00. Following the completion of the transaction, the director directly owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. The trade was a 40.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,211 shares of company stock valued at $4,199,331 in the last three months. Insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS Group AG raised its stake in Twist Bioscience by 28.6% in the fourth quarter. UBS Group AG now owns 662,317 shares of the company’s stock valued at $21,009,000 after purchasing an additional 147,389 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Twist Bioscience in the 1st quarter worth approximately $22,563,000. Tudor Investment Corp ET AL purchased a new position in Twist Bioscience in the 3rd quarter worth approximately $717,000. Pictet Asset Management Holding SA increased its holdings in shares of Twist Bioscience by 108.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 222,647 shares of the company’s stock worth $7,302,000 after buying an additional 115,880 shares during the last quarter. Finally, Baillie Gifford & Co. increased its holdings in shares of Twist Bioscience by 1.1% in the 4th quarter. Baillie Gifford & Co. now owns 1,276,195 shares of the company’s stock worth $40,481,000 after buying an additional 13,456 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.